{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026384","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.970189+00:00","generated_at":"2026-05-15T14:43:35.453480+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"SELLAS Life Sciences receives additional $16.1M from warrant exercises, total $42.6M since Dec 31","bullets":["Additional $16.1M in proceeds from warrant exercises since January 8, 2026.","Total warrant exercise proceeds since Dec 31, 2025: approximately $42.6M.","Shares outstanding as of March 11, 2026: 179,536,724.","Previously reported $26.5M in proceeds as of January 8, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026384","json":"https://secwatch.observer/filing/0001104659-26-026384.json","markdown":"https://secwatch.observer/filing/0001104659-26-026384.md","text":"https://secwatch.observer/filing/0001104659-26-026384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926026384/0001104659-26-026384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465926026384/tm268596d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:43:35.453480+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}